NeuroStar® Advanced Therapy Reaches Monumental Milestone of 1.7 Million Treatments in the US Non-drug, non-invasive NeuroStar has become a mainstream option for depression patients, and is now covered by most insurance companies and available in 49 states MALVERN,...
Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618 – Initial Objective...
Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer Senior Executive with Global Pharmaceutical Development and Manufacturing Experience WALTHAM, Mass.–(BUSINESS WIRE)–May 29, 2018– Deciphera Pharmaceuticals, Inc....
New Leaf Ventures Names Martin Mackay, Ph.D., as Senior Advisor Seasoned Biopharma R&D Executive Brings More Than 30 Years of Expertise to New Leaf and Its Portfolio of Healthcare and Technology Companies NEW YORK–(BUSINESS WIRE)–New Leaf Venture...
Neurana Pharmaceuticals Announces Completion of $60 Million Series A Financing Funding to advance novel drug for acute, painful muscle spasms and spasticity without sedation SAN DIEGO, California May 7, 2018 – Neurana Pharmaceuticals, Inc., a specialty pharmaceutical...
Recent Comments